Humanized anti-CD117 Monoclonal Antibody (JSP191)

Phase 1UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 15/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

MYELODYSPLASTIC SYNDROME; MDS

Conditions

MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML

Trial Timeline

Jul 8, 2020 → Dec 8, 2023

NCT ID

NCT04429191

About Humanized anti-CD117 Monoclonal Antibody (JSP191)

Humanized anti-CD117 Monoclonal Antibody (JSP191) is a phase 1 stage product being developed by Jasper Therapeutics for MYELODYSPLASTIC SYNDROME; MDS. The current trial status is unknown. This product is registered under clinical trial identifier NCT04429191. Target conditions include MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML.

What happened to similar drugs?

7 of 19 similar drugs in MYELODYSPLASTIC SYNDROME; MDS were approved

Approved (7) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04429191	Phase 1	UNKNOWN	Jul 8, 2020	Dec 8, 2023	MYELODYSPLASTIC SYNDROME; MDS
NCT02963064	Phase 1/2	Terminated	Mar 20, 2017	Jul 7, 2025	SCID

Competing Products

20 competing products in MYELODYSPLASTIC SYNDROME; MDS

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35
Decitabine	Johnson & Johnson	Phase 2	27